Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.

Read full text
Authors: Rumi Habib, Ryan S. Roark, Hui Li, Andrew Connell, Michael P Hogarty, Kshitij Wagh, Shuyi Wang, Lorie Marchitto, Ashwin N. Skelly, John W Carey, Kirsten J. Sowers, Kasirajan Ayyanathan
+39 more Samantha J. Plante, Frédéric Bibollet‐Ruche, Younghoon Park, Colby J. Agostino, Ajay Singh, Christian L. Martella, Emily E. Lewis, Juliette Rando, Neha Chohan, Jinery Lora, Wenge Ding, Mary S Campion, Chengyan Zhao, Weimin Liu, Yong Li, Xuduo Li, Bo Liang, Rohan Roy Chowdhury, Khaled Amereh, Elizabeth Van Itallie, Zizhang Sheng, Amrit R Ghosh, Katharine J Bar, Wilton B. Williams, Kevin Wiehe, Kevin O. Saunders, Robert J Edwards, Derek W. Cain, Mark G. Lewis, Facundo D Batista, Dennis R Burton, Raiees Andrabi, Daniel W. Kulp, Barton F Haynes, Bette Korber, Lawrence Shapiro, Peter D Kwong, Beatrice H. Hahn, George M Shaw
Cited by: 4

Abstract

Broadly neutralizing antibodies (bNAbs) are rarely elicited during HIV-1 infection. To identify obstacles to bNAb development, we longitudinally studied 122 rhesus macaques infected by 1 of 16 different simian-human immunodeficiency viruses (SHIVs). We identified the V2 apex region of the envelope (Env) as the most common bNAb target and a subset of Envs that preferentially elicited these antibodies. In 10 macaques, we delineated Env-antibody coevolution from B cell priming to bNAb development. Antibody phylogenies revealed permissive developmental pathways guided by evolving Envs that contained few mutations in or near the V2 apex C-strand, which were a sensitive indicator of apex-targeted responses. The absence of such mutations reflected a failure in bNAb priming. These results indicate that efficiency of B cell priming, and not complexities in Env-guided affinity maturation, is a primary obstacle to V2 apex bNAb elicitation in SHIV-infected macaques and identify specific HIV-1 Envs to advance as vaccine platforms.

Fields of Study & Subjects

HIV Research and Treatment T-cell and B-cell Immunology Immunotherapy and Immune Responses

Publication details

Journal / source
PubMed
Volume
11
Issue
116
Pages
eadz3933–eadz3933
Publication date
13 February 2026
Language
EN